Larvol Delta - Acumen-Pharmaceuticals-Announces-First-Subject-Dosed-in-Phase-1-Study-of-Subcutaneous-Sabirnetug-ACU193-for-Early-Alzheimers-Disease

sabirnetug SC (ACU193 SC) - Acumen Pharma

https://www.globenewswire.com/news-release/2024/07/29/2920163/0/en/Acumen-Pharmaceuticals-Announces-First-Subject-Dosed-in-Phase-1-Study-of-Subcutaneous-Sabirnetug-ACU193-for-Early-Alzheimer-s-Disease.html

Jul 29, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next